Head-to-Head

Halozyme Therapeutics, Inc. vs. Tectonic Therapeutic, Inc. Common Stock

HALO

Halozyme Therapeutics, Inc.

$107.72 +1.16%

VS TECX

Tectonic Therapeutic, Inc. Common Stock

$31.22 +4.28%

Halozyme Therapeutics, Inc. and Tectonic Therapeutic, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.

Size & Scale

HALOTECX
Market Cap $12.09 billion $585.31 million
Revenue (TTM) $1.66 billion
Net Income (TTM) $413.60 million

HALO leads on 1 of 1 size & scale factors.

Valuation

HALOTECX
P/E Ratio 31.41
Price / Book 84.20
Price / Sales 7.26

HALO and TECX split the valuation factors evenly.

Profitability

HALOTECX
Net Margin 24.86%
Return on Equity 288.13%

HALO and TECX split the profitability factors evenly.

Risk & Sentiment

HALOTECX
Short Interest 9.79% 0.09%

TECX leads on 1 of 1 risk & sentiment factors.

Dig deeper: HALO overview, HALO financials, TECX overview, TECX financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.